TREATMENT OUTCOMES OF SEROUS CARCINOMA OF ENDOMETRIUM: EXPERIENCE FROM A TERTIARY CANCER CENTER IN EASTERN INDIA

Résumé du livre

Background & Introduction:Serous endometrial carcinoma is an aggressive form of endometrial carcinoma accounting for 5% of all endometrial tumors. It is associated with increased mortality and is liable for 40% of the deaths due to endometrial cancers. There is scarcity of outcome data in an Indian setting. Hence, we undertook this study to analyze the clinical characteristics, histopathological features, recurrence and survival outcomes.Methods:This is a retrospective observational study of all cases of serous carcinoma endometrium diagnosed and treated at our institute from June 2011 to March 2018. The data was collected from the electronic hospital database. Survival analysis was done using Kaplan Meir method.Results:A total of 68 patients were analyzed. Median age at diagnosis was 62 years (30-75). The distribution of FIGO stage at diagnosis was: 21 (30.9%) in Stage I, 4 (5.9%) in Stage II, 17 (25%) in Stage III and 26 (38.2%) in Stage IV. Of these 68 patients, 47 underwent surgery, and 13 received palliative chemotherapy in view of stage IV disease, 8 patient received adjuvant treatment after undergoing surgery outside. 32 patients underwent surgery via laparotomy and 15 patients had a laparoscopic surgery performed. Systemic chemotherapy was the commonest form of adjuvant treatment, administered in 24 of the 47 patients who underwent surgery. The median follow up duration was 14 months. There were 34 (50%) recurrences and 23 (33.8%) deaths. The median recurrence free survival (RFS) was 23 months and estimated 5 year overall survival (OS) is 55.5% with recurrence and mortality noted more frequently in advanced stage.Conclusions:Serous carcinoma is an aggressive form of endometrial carcinoma commonly presenting in advanced stage. However, patients with early stage disease have better RFS and OS compared to advanced stage disease.